RA Research, Resources, and Rheumatology Archives | Page 10 of 19 | Rheumatoid Arthritis Warrior

RA Research, Resources, and Rheumatology

The Immune Fingerprint and Rheumatoid Disease

Kelly O'Neill 26 Comments , ,
I’ve made up another term because I haven’t heard of anything suitable: “immune fingerprint.” It occurred to me that while we talk about how the disease Rheumatoid Arthritis (or Rheumatoid Autoimmune Disease) affects us, one key to understanding disease activity may be considering how we affect the disease. If a disease disrupts the immune system, causing...Continue reading      26 Comments » Read more

Are Biosimilars Justice in Competition for Biologics Like Enbrel?

Kelly O'Neill 13 Comments , ,
The FDA definition of biosimilars and a pathway to approval Biosimilars are pharmaceuticals that are similar to biologics such as Enbrel and Humira, but not chemically identical as with generic drugs. If the unique molecules used to create a biologic (from living proteins) such as Enbrel are not cloned, but carefully imitated, they are considered “biosimilar.”...Continue reading      13 Comments » Read more
what causes rheumatoid arthritis trigger

What Causes Rheumatoid Arthritis to Trigger?

Kelly O'Neill 94 Comments , , ,
What causes Rheumatoid Arthritis? (UPDATED) I never asked “why me?” when diagnosed with RA because it’s not my way of thinking. Yet people do ask me “HOW did this happen?” or “What triggers RA?” What causes rheumatoid arthritis - that's the multi-billion dollar question! Here’s a summary of what is known at this point. There are a...Continue reading      94 Comments » Read more

The HAQ’s, the RAPID’s & the Rest: 3 Reasons It’s a Moot Point

Kelly O'Neill 43 Comments , ,
So often when I’m listening to a scientific presentation about clinical care for Rheumatoid Arthritis, I would do the face-palm head-smack, if my shoulder would let me. Depending on who can hear me, I mutter softly or wail sarcastically, “If it’s not done, does this matter?” One example is measuring RA disease activity, especially with...Continue reading      43 Comments » Read more

Pfizer’s JAK inhibitor Tofacitinib EMA Application Validated

Kelly O'Neill 10 Comments ,
Pfizer JAK-3 press release “Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis: Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by...Continue reading      10 Comments » Read more

Mayo Clinic Video Interview: Patients at ACR Scientific Meeting

Kelly O'Neill 11 Comments , ,
Some of you may be puzzled about what I’m doing in Chicago. So here’s a brief summary and a video interview with Mayo Clinic News Blog telling why patients are interested in a scientific meeting like the ACR Scientific Meeting. What happens at the American College of Rheumatology Scientific Meeting? “The ACR/ARHP Annual Scientific Meeting will be...Continue reading      11 Comments » Read more

When Rheumatology Is Sexy

Kelly O'Neill 16 Comments ,
If medicine can be sexy the way a new car or an iPhone is, what about rheumatology? Is there anything desirable or exciting there? Possibly, according to rheumatologist Ronan Kavanagh who wrote “The sexiness and cool of rheumatology.” Mostly, rheumatologists examine things that healthy people look away from: disability, deformity, and pain. The father of modern...Continue reading      16 Comments » Read more
“imaware™
    Advertisement

Would You Like Free Email Updates?

Stay in touch with RA Warrior.

We respect your privacy. Your email address will never be shared.